142 related articles for article (PubMed ID: 15276086)
1. Rapid induction of P-glycoprotein expression by high permeability compounds in colonic cells in vitro: a possible source of transporter mediated drug interactions?
Collett A; Tanianis-Hughes J; Warhurst G
Biochem Pharmacol; 2004 Aug; 68(4):783-90. PubMed ID: 15276086
[TBL] [Abstract][Full Text] [Related]
2. Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells.
Sachs-Barrable K; Thamboo A; Lee SD; Wasan KM
J Pharm Pharm Sci; 2007; 10(3):319-31. PubMed ID: 17727795
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound.
Spahn-Langguth H; Baktir G; Radschuweit A; Okyar A; Terhaag B; Ader P; Hanafy A; Langguth P
Int J Clin Pharmacol Ther; 1998 Jan; 36(1):16-24. PubMed ID: 9476144
[TBL] [Abstract][Full Text] [Related]
4. The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux.
Hayeshi R; Masimirembwa C; Mukanganyama S; Ungell AL
Eur J Pharm Sci; 2006 Sep; 29(1):70-81. PubMed ID: 16846720
[TBL] [Abstract][Full Text] [Related]
5. Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability.
Cao X; Yu LX; Barbaciru C; Landowski CP; Shin HC; Gibbs S; Miller HA; Amidon GL; Sun D
Mol Pharm; 2005; 2(4):329-40. PubMed ID: 16053336
[TBL] [Abstract][Full Text] [Related]
6. Comparison of P-glycoprotein-mediated drug-digoxin interactions in Caco-2 with human and rodent intestine: relevance to in vivo prediction.
Collett A; Tanianis-Hughes J; Carlson GL; Harwood MD; Warhurst G
Eur J Pharm Sci; 2005 Dec; 26(5):386-93. PubMed ID: 16153812
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide does not interact with P-glycoprotein.
Zimmermann C; Gutmann H; Drewe J
Cancer Chemother Pharmacol; 2006 May; 57(5):599-606. PubMed ID: 16136308
[TBL] [Abstract][Full Text] [Related]
8. Human intestinal P-glycoprotein activity estimated by the model substrate digoxin.
Larsen UL; Hyldahl Olesen L; Guldborg Nyvold C; Eriksen J; Jakobsen P; Østergaard M; Autrup H; Andersen V
Scand J Clin Lab Invest; 2007; 67(2):123-34. PubMed ID: 17365992
[TBL] [Abstract][Full Text] [Related]
9. Influence of beta-adrenergic antagonists, H1-receptor blockers, analgesics, diuretics, and quinolone antibiotics on the cellular accumulation of the anticancer drug, daunorubicin: P-glycoprotein modulation.
Ibrahim S; Peggins J; Knapton A; Licht T; Aszalos A
Anticancer Res; 2001; 21(2A):847-56. PubMed ID: 11396174
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin.
Barthomeuf C; Grassi J; Demeule M; Fournier C; Boivin D; Béliveau R
Cancer Chemother Pharmacol; 2005 Aug; 56(2):173-81. PubMed ID: 15824923
[TBL] [Abstract][Full Text] [Related]
11. A flow cell assay for evaluation of whole cell drug efflux kinetics: analysis of paclitaxel efflux in CCRF-CEM leukemia cells overexpressing P-glycoprotein.
Lin JT; Sharma R; Grady JJ; Awasthi S
Drug Metab Dispos; 2001 Feb; 29(2):103-10. PubMed ID: 11159798
[TBL] [Abstract][Full Text] [Related]
12. Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure.
He H; Lyons KA; Shen X; Yao Z; Bleasby K; Chan G; Hafey M; Li X; Xu S; Salituro GM; Cohen LH; Tang W
Xenobiotica; 2009 Sep; 39(9):687-93. PubMed ID: 19569734
[TBL] [Abstract][Full Text] [Related]
13. Several major antiepileptic drugs are substrates for human P-glycoprotein.
Luna-Tortós C; Fedrowitz M; Löscher W
Neuropharmacology; 2008 Dec; 55(8):1364-75. PubMed ID: 18824002
[TBL] [Abstract][Full Text] [Related]
14. Induction of P-glycoprotein expression and function in human intestinal epithelial cells (T84).
Haslam IS; Jones K; Coleman T; Simmons NL
Biochem Pharmacol; 2008 Oct; 76(7):850-61. PubMed ID: 18703021
[TBL] [Abstract][Full Text] [Related]
15. Chalcogenopyrylium dyes as inhibitors/modulators of P-glycoprotein in multidrug-resistant cells.
Sawada GA; Raub TJ; William Higgins J; Brennan NK; Moore TM; Tombline G; Detty MR
Bioorg Med Chem; 2008 Nov; 16(22):9745-56. PubMed ID: 18849167
[TBL] [Abstract][Full Text] [Related]
16. Co-treatment with grapefruit juice inhibits while chronic administration activates intestinal P-glycoprotein-mediated drug efflux.
Panchagnula R; Bansal T; Varma MV; Kaul CL
Pharmazie; 2005 Dec; 60(12):922-7. PubMed ID: 16398269
[TBL] [Abstract][Full Text] [Related]
17. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein.
Keogh JP; Kunta JR
Eur J Pharm Sci; 2006 Apr; 27(5):543-54. PubMed ID: 16406207
[TBL] [Abstract][Full Text] [Related]
18. Venlafaxine induces P-glycoprotein in human Caco-2 cells.
Ehret MJ; Levin GM; Narasimhan M; Rathinavelu A
Hum Psychopharmacol; 2007 Jan; 22(1):49-53. PubMed ID: 17191263
[TBL] [Abstract][Full Text] [Related]
19. Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line.
Romiti N; Tramonti G; Chieli E
Toxicol Appl Pharmacol; 2002 Sep; 183(2):83-91. PubMed ID: 12387747
[TBL] [Abstract][Full Text] [Related]
20. Can celecoxib affect P-glycoprotein-mediated drug efflux? A microPET study.
de Vries EF; Doorduin J; Vellinga NA; van Waarde A; Dierckx RA; Klein HC
Nucl Med Biol; 2008 May; 35(4):459-66. PubMed ID: 18482683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
